Search PubMed⌕ Search

Biomedical subjects

Tom Mikkelsen

Publications and source records attributed to Tom Mikkelsen.

21 records · Page 2Linked to original sources

Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas.

Degradation of extracellular matrix proteins by proteases such as the cysteine protease cathepsin B is critical to malignant progression. We have established that procathepsin B presents on the surface of tumor cells through its interaction with the annexin II tetramer [Mai et al., J. Biol. Chem. 275 (2000),12806-12812]. Cathepsin B activity can also be detected on the tumor cell surface and in their culture medium. Interestingly, the annexin II tetramer also interacts with extracellular matrix proteins, such as collagen I, fibrin and tenascin-C. Both cathepsin B and tenascin-C are expressed at high levels in malignant tumors, especially at the invasive edges of tumors, and are implicated in tumor angiogenesis. In this study, we report that tenascin-C can be degraded by cathepsin B in vitro. We demonstrate by immunohistochemistry that both cathepsin B and tenascin-C are expressed highly in malignant anaplastic astrocytomas and glioblastomas as compared to normal brain tissues. Interestingly, cathepsin B and tenascin-C were also detected in association with tumor neovessels. We suggest that interactions between cathepsin B and tenascin-C are involved in the progression of gliomas including the angiogenesis that is a hallmark of anaplastic astrocytomas.

Astrocytoma↗

Developing a brain tumor center.

The development of a multidisciplinary brain tumor center requires many steps, from selection of leaders to garnering institutional support, growing the clinical neuro-oncology business, and building multidisciplinary involvement especially with the tumor board. Key clinicians and researchers need to be recruited to develop the academic enterprise, and acquiring external endorsement and philanthropy support can be critical factors in maintaining institutional support and in meeting special needs of the center. The process of managing money, space and support personnel, and the maintenance of the overall program are important as well. Our views on building a brain tumor center reflect our specific situation in developing and growing the Hermelin Brain Tumor Center at Henry Ford Hospital in Detroit and hence might not be precisely applicable to the development of centers elsewhere.

Academic Medical Centers↗

Angiogenesis in glioma: molecular mechanisms and roadblocks to translation.

Gliomas are characterized by very high levels of neo-vascularization holding out the hope that therapies aimed at angiogenesis will have a significant impact on this intractable family of tumors. Intense research into the molecular mechanisms that drive the formation of new blood vessels in response to tumor growth has revealed a great deal of complexity, at the heart of which are competing pro- and anti-angiogenic influences. The relevant signaling pathways, and how they might be manipulated to interfere in the promotion of vessel growth are discussed. Several types of anti-angiogenic lead compounds are already in clinical trials, but assessing their impact on brain tumors is not straightforward. We discuss in depth some of the practical aspects of using imaging to more meaningfully follow tumor progression and response to treatment, which is particularly relevant to the use of therapies that target blood flow directly, which is fundamental to modern imaging modalities.

Angiogenesis Inhibitors↗